drugset / Trial / NCT03262298
Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The study will evaluate safety and efficacy of the CD22-targeted chimeric antigen receptor modified-T cell(CAR-T) cells in the treatment of B-cell Malignancies.
Timeline
- Start
- 2017-08-20
- Primary completion
- 2021-08-20
- Completion
- 2022-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-CD22-CAR-transduced T cells | Cell therapy | — | Other |